Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alzheimer’s Therapies “Best Buys” Named By Consumer Reports

This article was originally published in The Pink Sheet Daily

Executive Summary

Aricept, Razadyne and Namenda are selected for the list despite the poor response associated with Alzheimer’s.

You may also be interested in...



Pfizer/Eisai’s Aricept Becomes First Treatment Approved For All Degrees of Alzheimer’s

Because Aricept is often used in combination with Namenda, though, Forest says it is not concerned about market share erosion.

Pfizer/Eisai’s Aricept Becomes First Treatment Approved For All Degrees of Alzheimer’s

Because Aricept is often used in combination with Namenda, though, Forest says it is not concerned about market share erosion.

Medco Savings Tool Spotlights Consumer Reports’ “Best Buy” Drugs

PBM will feature link to Consumer Reports Best Buy Drugs for certain medication classes.

Topics

UsernamePublicRestriction

Register

LL1126093

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel